Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efocipegtrutide - Hanmi Pharmaceutical

Next Previous
Drug Profile

Efocipegtrutide - Hanmi Pharmaceutical

Alternative Names: GLP-1/GIP/glucagon triagonist - Hanmi Pharmaceutical; HM-15211; LAPS-triple agonist

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antidementias; Antifibrotics; Antihyperglycaemics; Antihyperlipidaemics; Antiparkinsonians; Hepatoprotectants; Obesity therapies; Peptides
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis; Idiopathic pulmonary fibrosis; Primary biliary cirrhosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis
  • Preclinical Idiopathic pulmonary fibrosis
  • No development reported Hepatic fibrosis; Non-alcoholic fatty liver disease
  • Discontinued Alzheimer's disease; Dyslipidaemias; Multiple sclerosis; Obesity; Parkinson's disease; Type 2 diabetes mellitus

Most Recent Events

  • 03 Dec 2024 Pharmacodynamics data from the preclinical studies in Non-alcoholic steatohepatitis released by Hanmi Pharmaceutical
  • 15 Nov 2024 Pharmacodynamics data from preclinical studies in Liver injury presented at the 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2024)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Non-alcoholic-fatty-liver-disease in USA (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top